[PDF] Top 20 Los costos financieros del microcrédito en Colombia
Has 10000 "Los costos financieros del microcrédito en Colombia" found on our website. Below are the top 20 most common "Los costos financieros del microcrédito en Colombia".
<p>Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives</p>
... early treatment of skin toxicity has been proposed to improve the safety pro fi le of ...received dacomitinib at the dose of 45 mg with a planned interruption from day 11 to day 14 of cycle ...when ... See full document
19
Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
... Additionally, quality-of-life analysis was not considered in the present study. Thus, due to a lack of specific data in Greece, the study ignored potential differences between the two treatments regarding the ... See full document
11
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
... first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations, based on seven prospective randomized Phase III ...EGFR-mutant ... See full document
9
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
... Finally, pembrolizumab is also being evaluated in the com- bination with SOC chemotherapy in the adjuvant setting. One of the proposed benefits of using immunotherapy in the adju- vant setting is to create a reservoir of ... See full document
8
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
... upon cancer cells by interfering with aberrant specific activated pathways needed for tumor growth, angiogenesis and cell ...the treatment of locally advanced or metastatic ... See full document
15
<p>Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the <em>KDR</em> Gene Polymorphism</p>
... with NSCLC in China. Therefore, patients with advanced NSCLC who progressed or relapsed after standard therapy from January 2015 to December 2018 in the Department of Medical Oncology of The Fourth Hospital ... See full document
15
Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes
... of metastatic lymph ...of metastatic lymph nodes into groups: 1–3, 4–6, >6 [21], 1–4, 4–14, >14 [23], 1–3, 4–6, 7–9, ≥10 [20] can be found in ...of metastatic nodes, as well as, it is currently ... See full document
46
Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
... This present review identified several gaps in the cur- rent literature. First, the role of BEV in other settings (such as adjuvant or second-line) and thus its economic values remained unknown. Second, in the era of ... See full document
6
<p>Clinical utility of ramucirumab in non-small-cell lung cancer</p>
... based treatment regimen would no longer be ...preferred treatment option for patients who do not have actionable driver mutation, based on data from two landmark studies, namely, KEYNOTE-189 and ...ferred ... See full document
65
<p>Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team</p>
... Good Clinical Practice (Regulation of Order No.3). Clinical data were collected on patients who received antitumor treatment, such as sex, age, pathological type, genetic mutations, and major ... See full document
16
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
... 0.64–0.96, P= ...first-line treatment in all patients with advanced non- squamous ...ALK-positive NSCLC have been recently presented, with encouraging results in terms of both activity and ... See full document
16
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
... the treatment of patients with advanced non-small-cell lung can- cer (NSCLC) based on Phase II clinical trials since ...EGFR-TKI treatment, and gefitinib, which is ... See full document
19
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
... oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor ...including ... See full document
62
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
... from NSCLC had identified novel alterations in genes in- volved in chromatin modification and DNA repair path- ways, novel metabolic enzymes, as well as aberration of cell fate determination factor DACH1 ... See full document
11
<p>Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives</p>
... (ALK+) lung cancers compose a small subset of non-small cell lung cancer (NSCLC), with rapidly expanded ...the treatment of ALK+ NSCLC ...of ... See full document
11
<p>A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation</p>
... across NSCLC health states, most were based on the same concept of clinical condition or symptom, but the study methods, the components of the numerator ... See full document
30
Afatinib for the treatment of metastatic non-small cell lung cancer
... with non-small cell lung cancer (NSCLC) harboring sensitizing mutations in the tyrosine kinase (TKI) domain has led to a significant change in the management of this ...and ... See full document
18
Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer
... primary NSCLC who underwent curative- intent thoracic surgery in Fudan University Shanghai Cancer Center (FUSCC) from January 2012 to December 2012 were identified, including 101 patients with ...pivotal ... See full document
11
Clinical potential of gene mutations in lung cancer
... advanced NSCLC that progressed after treatment with erlotinib, gefitinib, or both compared to placebo group ...months P < ...advanced NSCLC had an overall response rate of 58 % [19, ... See full document
209
<p>Update on liquid biopsy in clinical management of non-small cell lung cancer</p>
... for NSCLC. It not only revolutionizes the treatment strategy for NSCLC, but also prolongs the survival for advanced ...tumors non-invasively and ... See full document
5
Related subjects